品牌 | 货号 | 包装单位 | 货期 | CAS | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
---|---|---|---|---|---|---|---|---|
阿拉丁 | G127527-10mg | 10mg | 现货 | 937174-76-0 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK-690693 |
Moligand™, ≥98% |
|
|
阿拉丁 | G127527-50mg | 50mg | 现货 | 937174-76-0 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK-690693 |
Moligand™, ≥98% |
|
|
阿拉丁 | G127527-5mg | 5mg | 现货 | 937174-76-0 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK-690693 |
Moligand™, ≥98% |
|
|
阿拉丁 | G127527-100mg | 100mg | 现货 | 937174-76-0 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK-690693 |
Moligand™, ≥98% |
|
|
阿拉丁 | G409035-1ml | 1ml | 现货 | 937174-76-0 |
GSK690693 GSK690693 |
Moligand™, 10mM in DMSO |
|
|
麦克林 | G873199-1mg | 1mg | 订前询问 | 937174-76-0 |
GSK690693 GSK690693 |
0.99 |
|
|
罗恩 | R032709-1mg | 1mg | 现货 | 937174-76-0 |
土大黄甙 GSK690693 |
99% |
|
|
MARY | MR1438110-1mg | 1mg | 订前咨询 | 937174-76-0 |
土大黄甙 GSK690693 |
99% |
|
|
源叶 | S81130-5mg | 5mg | 期货,请咨询 | 937174-76-0 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK690693 |
≥98% |
|
|
源叶 | S81130-10mg | 10mg | 期货,请咨询 | 937174-76-0 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK690693 |
≥98% |
|
|
源叶 | S81130-50mg | 50mg | 期货,请咨询 | 937174-76-0 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK690693 |
≥98% |
|
|
源叶 | S81130-100mg | 100mg | 期货,请咨询 | 937174-76-0 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK690693 |
≥98% |
|
|
韶远 | SY328472-0.05g | 0.05g | 现货 | 937174-76-0 |
(S)-4-[2-(4-氨基-1,2,5-噁二唑-3-基... (S)-4-[2-(4-Amino-1,2,5-oxad... |
≥95% |
|
|
源叶 | S59417-1ml | 1ml | 期货,请咨询 | 937174-76-0 |
GSK690693 GSK690693 |
10mM in DMSO |
|
|
毕得 | BD234847-5mg | 5mg | 现货 | 937174-76-0 |
(S)-4-(2-(4-氨基-1,2,5-额二唑-3-基... (S)-4-(2-(4-Amino-1,2,5-oxad... |
99% |
|
|
毕得 | BD234847-10mg | 10mg | 现货 | 937174-76-0 |
(S)-4-(2-(4-氨基-1,2,5-额二唑-3-基... (S)-4-(2-(4-Amino-1,2,5-oxad... |
99% |
|
|
毕得 | BD234847-50mg | 50mg | 现货 | 937174-76-0 |
(S)-4-(2-(4-氨基-1,2,5-额二唑-3-基... (S)-4-(2-(4-Amino-1,2,5-oxad... |
99% |
|
|
毕得 | BD234847-1mg | 1mg | 现货 | 937174-76-0 |
(S)-4-(2-(4-氨基-1,2,5-额二唑-3-基... (S)-4-(2-(4-Amino-1,2,5-oxad... |
99% |
|
|
毕得 | BD234847-25mg | 25mg | 现货 | 937174-76-0 |
(S)-4-(2-(4-氨基-1,2,5-额二唑-3-基... (S)-4-(2-(4-Amino-1,2,5-oxad... |
99% |
|
|